Outlook Therapeutics
OTLK
14 hedge funds and large institutions have $1.73M invested in Outlook Therapeutics in 2019 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 5 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 2
13% more capital invested
Capital invested by funds: $1.53M → $1.73M (+$198K)
0.07% more ownership
Funds ownership: 0.09% → 0.16% (+0.07%)
0% more funds holding
Funds holding: 14 → 14 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$809K |
| 2 |
LA
LVW Advisors
Pittsford,
New York
|
+$659K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$75.7K |
| 4 |
Squarepoint
New York
|
+$64.5K |
| 5 |
CC
Chicago Capital
Chicago,
Illinois
|
+$45.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$630K |
| 2 |
Renaissance Technologies
New York
|
-$83K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$25.1K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$10K |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$9.23K |
OTLK Hedge Fund Activity: Q2 2019 in Review
14 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q2 2019, worth a combined $1.73M — up 13% from $1.53M a quarter earlier.
Fund positioning in OTLK was balanced in Q2 2019: 5 funds opened new positions, 5 closed out, 6 added to existing stakes and 2 trimmed.
The largest buyer was Vanguard Group, adding an estimated $809K. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $630K sold.
- 14 institutional investors held Outlook Therapeutics (OTLK) as of Q2 2019, unchanged from Q1 2019.
- Funds reported $1.73M of Outlook Therapeutics stock for Q2 2019, up 13% quarter-over-quarter.
- 5 funds opened new Outlook Therapeutics positions in Q2 2019 and 5 closed out, a net change of 0 holders.
- The largest Outlook Therapeutics buyer in Q2 2019 was Vanguard Group, an estimated $809K added.
- The largest Outlook Therapeutics seller in Q2 2019 was Avoro Capital Advisors, an estimated $630K sold.
Based on aggregated 13F filings for Q2 2019.